Bullous Pemphigoid Associated With a New Combination Checkpoint Inhibitor Immunotherapy

Fontecilla Natalia M.; Khanna Trisha; Bayan Claire-Audrey Y.; Antonov Nina A.; Geskin Larisa J.

首页> 外文期刊>Journal of drugs in dermatology: JDD >Bullous Pemphigoid Associated With a New Combination Checkpoint Inhibitor Immunotherapy

【24h】

Bullous Pemphigoid Associated With a New Combination Checkpoint Inhibitor Immunotherapy

机译：大疱性毒物与新的组合检查点抑制剂免疫疗法相关

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Novel immunotherapies including antibodies to programmed death ligand 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) have become common therapies for neoplasms including metastatic melanoma and non-small cell lung cancer (NSCLC). Dermatologic toxicity is the most common adverse event associated with these immunotherapies. We report a case of bullous pemphogoid (BP) in a patient receiving combination durvalumab and tremelimumab, two newer immunotherapy checkpoint inhibitors under investigation in phase III trials.

机译：包括针对编程死亡配体1（PD-1）和细胞毒性T淋巴细胞相关抗原4（CTLA-4）的抗体的新型免疫疗法已成为包括转移性黑素瘤和非小细胞肺癌（NSCLC）的肿瘤的常见疗法。皮肤病学毒性是与这些免疫治疗相关的最常见的不良事件。我们在接受组合Durvalumab和Tremetimumab的患者中报告了大疱的普通骨折（BP）的情况，在III期试验中调查的两种新免疫疗法检查点抑制剂。

著录项

来源
《Journal of drugs in dermatology: JDD》 |2019年第1期|共2页
作者
Fontecilla Natalia M.; Khanna Trisha; Bayan Claire-Audrey Y.; Antonov Nina A.; Geskin Larisa J.;
展开▼
作者单位

Columbia Univ Med Ctr New York NY 10027 USA;

Columbia Univ Med Ctr New York NY 10027 USA;

Columbia Univ Med Ctr New York NY 10027 USA;

Columbia Univ Med Ctr New York NY 10027 USA;

Columbia Univ Med Ctr New York NY 10027 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Bullous Pemphigoid Associated With a New Combination Checkpoint Inhibitor Immunotherapy [J] . Fontecilla Natalia M., Khanna Trisha, Bayan Claire-Audrey Y., Journal of drugs in dermatology: JDD . 2019,第1期

机译：大疱性毒物与新的组合检查点抑制剂免疫疗法相关
2. Immunotherapy for Prostate Cancer: Where Do We Go From Here? PART 2: Checkpoint Inhibitors, Immunotherapy Combinations, Tumor Microenvironment Modulation, and Cellular Therapies [J] . Patel Amar, Fong Lawrence Oncology . 2018,第6期

机译：前列腺癌的免疫疗法：我们从这里去哪里？第2部分：检查点抑制剂，免疫疗法组合，肿瘤微环境调制和细胞疗法
3. Immunotherapy for Prostate Cancer: Where Do We Go From Here? PART 2: Checkpoint Inhibitors, Immunotherapy Combinations, Tumor Microenvironment Modulation, and Cellular Therapies [J] . Patel Amar, Fong Lawrence Oncology . 2018,第6期

机译：前列腺癌的免疫疗法：我们从这里去哪里？第2部分：检查点抑制剂，免疫疗法组合，肿瘤微环境调制和细胞疗法
4. Advances of Immune Checkpoint Inhibitors in Tumor Immunotherapy [C] . Qiao Guo Annual International Conference on Material Science and Environmental Engineering . 2018

机译：免疫检查点抑制剂在肿瘤免疫疗法中的进展
5. Structural and functional analysis of bullous pemphigoid antigen1 (BPAG1) [D] . Jefferson, Julius J. 2007

机译：大疱性类天疱疮抗原1（BPAG1）的结构和功能分析
6. Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers [O] . Christian D. Sadik, Ewan A. Langan, Ralf Gutzmer, 2020

机译：六种德国皮肤病学中心检查点抑制剂治疗相关病例的回顾性分析
7. Anti–PD1 Immune Checkpoint Inhibitor–Induced Bullous Pemphigoid in Metastatic Melanoma and Non–Small Cell Lung Cancer [O] . Gabrielle Schwartzman, Meagan McGinley Simpson, Ryan Jones, 2020

机译：抗PD1免疫检查点抑制剂诱导的大疱性黑色瘤和非小细胞肺癌中的大疱性斑态
8. Evaluation of the Immunologic Impact of RAF Inhibitors to Guide Optimal Combination of RAF Inhibitors and Immunotherapy for the Treatment of Advanced Melanoma. [R] . Callahan, M., Merghoub, T. 2016

机译：评估RaF抑制剂对引导RaF抑制剂和免疫疗法治疗晚期黑色素瘤的最佳组合的免疫影响。

Bullous Pemphigoid Associated With a New Combination Checkpoint Inhibitor Immunotherapy

摘要

著录项

相似文献

相关主题

期刊订阅